The FTC just went after ‘bundling’ in Amgen’s $28B deal. Will it put a chill on future M&A?

The FTC’s surprising and potentially risky attempt to block Amgen’s proposed $28 billion buyout of Horizon Therapeutics has raised concerns about federal oversight of a sector gearing up for an active M&A year. In a lawsuit filed Tuesday in federal court, the FTC argued that the merger would allow Amgen…